Phase II study of dasatinib for CML-CP patients with suboptima/failure after treatment of imatinib
Not Applicable
- Conditions
- suboptimal/failure response CML-CP patients despite imatinib treatment
- Registration Number
- JPRN-UMIN000004280
- Lead Sponsor
- Fukuoka CML stem cell research group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
CML-BC and AP
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method